A Long Term Safety Study With Atrasentan

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

July 31, 2001

Study Completion Date

June 30, 2007

Conditions
Prostate CancerAdenocarcinoma
Interventions
DRUG

Atrasentan

Trial Locations (15)

10003

Beth Isreal Medical Center, Phillips Ambulatory Care Ceneter, New York

14609

ViaHealth Rochester General Hospital Center for Urology, Rochester

15232

University of Pittsburgh Department of Urology, Pittsburgh

31043

Hoptial de Ranguell Service d'Urologie, Toulouse

32589

Prostate Oncology Specialists, Marina del Rey

33180

South Florida Medical Research, Aventura

90505

Western Clinical Research, Inc., Torrance

97477

Oregon Urology Specialist, Division of Clinical Research, Springfield

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 1M9

CroMedia Prime/Prime Trials Vancouver Hospital, Vancouver

3V2CAN

Ken Janz MD, Burlington

L8N 4A6

McMaster Institute of Urology, Hamilton

H3A1A1

McGill University Health Center Royal VIctoria Hosptial, Montreal

Unknown

University Hospital Rotterdam, Department of Urology, Rotterdam

CW1 4QT

Leighton Hospital Urology Research Dept., Michael Heal Outpatients Dept., Crewe

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY